It is worst in the first 24 to 48 hours after each dose increase and typically improves with continued use at any given dose level
The American Journal of Clinical Nutrition, 104(2), 362370
A retrospective study explored the impact of prior GLP-1RA treatment on the response of DR patients to subsequent intravitreal anti-VEGF injections and other conventional ophthalmic therapy (Michaeli et al., 2024)
These references are included for educational purposes only and do not constitute claims of safety, efficacy, or approval for human or animal use
[DOI] [PMC free article] [PubMed] [Google Scholar] 95.Singh H, Natt NK, Nim DK
Similarly, ophthalmological endpoints were investigated adjusting for (1) papilledema degree, (2) pRNFL thickness, (3) GCL volume, or (3) ONSD at baseline as appropriate and in a second step also for weight loss to evaluate potential independent treatment effects of GLP-1-RAs